To include your compound in the COVID-19 Resource Center, submit it here.

Tivantinib: Development discontinued

ArQule discontinued development of tivantinib to treat relapsed or refractory germ cell tumors after an open-label, international Phase II trial in 25

Read the full 225 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE